TMDX logo

TRANSMEDICS GROUP INC

TMDXNASDAQ
๐Ÿ† #1796 by market capEarnings Nov 5US Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track TMDX
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$2.32B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
25.8%
High Growth
๐Ÿ“ŠGross Margin
58.7%
Healthy
๐Ÿ’ตFCF Margin
13.6%
Healthy
โš–๏ธP/S Ratio
3.5x
Fair
Otter Score
โ€”
Insufficient data
No chart data available for TMDX.

Trading Snapshot

Day Range
โ€”
52-Week Range
$60.11 โ€“ $156.00
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
34.7M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
15.3
P/S Ratio
3.5x
EPS (TTM)
$3.73
Dividend Yield
โ€”
TMDX logo

TRANSMEDICS GROUP INC

TMDX
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About TRANSMEDICS GROUP INC

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.